XOMA and Aragen Bioscience Announce Antibody Humanization Services Agreement
BERKELEY & MORGAN HILL, Calif.–(BUSINESS WIRE)–XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, and Aragen Bioscience, Inc., a provider of high-content preclinical research and development services, have entered into an agreement under which Aragen Bioscience will provide its clients access to XOMA’s proprietary Human Engineering™ technology for antibody humanization. Financial terms were not disclosed.
“We believe that pairing our Human Engineering technology and know-how with Aragen Bioscience’s cell line development experience and expertise is an excellent way to make this technology available to the pharmaceutical and biotech industries”
The Human Engineering technology enables the derivation of humanized variable region amino acid sequences from mature mouse variable region amino acid sequences. “Access to XOMA’s extensive technology and expertise in antibody humanization allows Aragen Bioscience to provide its customers a seamless transition from murine antibody discovery and sequencing to antibody testing, variable domain humanization, stable and transient expression, cell line development and pre-clinical production services. The addition of XOMA’s technology to our services enables our clients to quickly access antibody humanization technology that is recognized throughout the industry as cutting-edge,” commented Aragen Bioscience’s President and CEO, Rick Srigley.
“We believe that pairing our Human Engineering technology and know-how with Aragen Bioscience’s cell line development experience and expertise is an excellent way to make this technology available to the pharmaceutical and biotech industries,” said Patrick J. Scannon, M.D., Ph.D., Executive Vice President and Chief Scientific Officer at XOMA.
XOMA is a leader in the discovery and development of novel antibody therapeutics. The company’s proprietary product pipeline includes a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary optimization and expression and manufacturing technologies that it uses for its own pipeline and in collaborations with pharmaceutical and biotechnology companies. XOMA’s fully integrated product development infrastructure in Berkeley, California extends from preclinical science to approval. For more information, please visit www.xoma.com.
About Aragen Bioscience
Aragen Bioscience, Inc., is a contract research and development services company located in the San Francisco Bay area. Aragen Bioscience specializes in recombinant cell line and hybridoma development, bench-scale cell culture and purification process development and production, primary and immortalized cell-based assays, in vivo models of human disease and custom immunological services. For more information, visit www.aragenbio.com.
Certain statements contained herein concerning product development and/or strategic goals or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.
These and other risks, including the generally unstable nature of current economic and financial market conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); XOMA’s ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; scale-up, manufacturing and marketing capabilities; changes in the status of existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations and their discretion in decision-making; market demand for products; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA’s financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA’s status as a Bermuda company, are described in more detail in XOMA’s most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA’s prospects.